It is worth noting that Temcell requires at least 8-12 infusions to achieve an equivalent clinical outcome compared with 2 infusions of CYP-001. This is a HUGE competitive advantage in COGS and overall cost of treatment. Note that the Temcell product is infused, so this requires the patient to either be a hospital in-patient or to attend an infusion center to receive treatment. OK if they are near the center, but a right pain if they need to travel.
MSB might be a little further down the track than CYP in terms of product development, but do not be fooled into thinking that this means it is somehow superior. First generation vs second generation.
Bottom line, we have a better, cheaper option.
- Forums
- ASX - By Stock
- 2020 - A Year Full Of Potentials
It is worth noting that Temcell requires at least 8-12 infusions...
-
- There are more pages in this discussion • 430 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CYP (ASX) to my watchlist
(20min delay)
|
|||||
Last
27.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $48.78M |
Open | High | Low | Value | Volume |
28.0¢ | 28.0¢ | 27.0¢ | $43.78K | 161.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 28180 | 27.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
28.0¢ | 10983 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 28180 | 0.270 |
2 | 10000 | 0.265 |
2 | 105000 | 0.260 |
2 | 10800 | 0.250 |
1 | 10000 | 0.245 |
Price($) | Vol. | No. |
---|---|---|
0.280 | 10983 | 1 |
0.285 | 2471 | 1 |
0.290 | 49421 | 2 |
0.295 | 25028 | 2 |
0.300 | 72500 | 2 |
Last trade - 13.12pm 07/10/2024 (20 minute delay) ? |
Featured News
CYP (ASX) Chart |